|
1
|
Ahmadloo N, Kani AA, Mohammadianpanah M,
et al: Treatment outcome and prognostic factors of adult
glioblastoma multiforme. J Egypt Natl Canc Inst. 25:21–30. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reardon DA, Herndon JE II, Peters K, et
al: Outcome after bevacizumab clinical trial therapy among
recurrent grade III malignant glioma patients. J Neurooncol.
107:213–221. 2012. View Article : Google Scholar
|
|
3
|
Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu
GL: Short-term anti-vascular endothelial growth factor treatment
elicits vasculogenic mimicry formation of tumors to accelerate
metastasis. J Exp Clin Cancer Res. 31:162012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maniotis AJ, Folberg R, Hess A, et al:
Vascular channel formation by human melanoma cells in vivo and in
vitro: vasculogenic mimicry. Am J Pathol. 155:739–752. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang SY, Ke YQ, Lu GH, et al: Vasculogenic
mimicry is a prognostic factor for postoperative survival in
patients with glioblastoma. J Neurooncol. 112:339–345. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang SY, Yu L, Ling GQ, et al:
Vasculogenic mimicry and its clinical significance in
medulloblastoma. Cancer Biol Ther. 13:341–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Land SC and Tee AR: Hypoxia-inducible
factor 1alpha is regulated by the mammalian target of rapamycin
(mTOR) via an mTOR signaling motif. J Biol Chem. 282:20534–20543.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su M, Feng YJ, Yao LQ, et al: Plasticity
of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo.
Int J Gynecol Cancer. 18:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paulis YW, Soetekouw PM, Verheul HM,
Tjan-Heijnen VC and Griffioen AW: Signalling pathways in
vasculogenic mimicry. Biochim Biophys Acta. 1806:18–28.
2010.PubMed/NCBI
|
|
11
|
Zhu P, Ning Y, Yao L, Chen M and Xu C: The
proliferation, apoptosis, invasion of endothelial-like epithelial
ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res.
29:1242010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Snijder B, Sacher R, Ramo P, et al:
Single-cell analysis of population context advances RNAi screening
at multiple levels. Mol Syst Biol. 8:5792012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu R, Yang K, Meng C, Zhang Z and Xu Y:
Vasculogenic mimicry is a marker of poor prognosis in prostate
cancer. Cancer Biol Ther. 13:527–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun W, Shen ZY, Zhang H, et al:
Overexpression of HIF-1α in primary gallbladder carcinoma and its
relation to vasculogenic mimicry and unfavourable prognosis. Oncol
Rep. 27:1990–2002. 2012.
|
|
15
|
Comito G, Calvani M, Giannoni E, et al:
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent
invasive growth and vasculogenic mimicry in melanoma cells. Free
Radic Biol Med. 51:893–904. 2011.
|
|
16
|
Abraham RT: mTOR as a positive regulator
of tumor cell responses to hypoxia. Curr Top Microbiol Immunol.
279:299–319. 2004.PubMed/NCBI
|
|
17
|
Wang L, Zhang ZG, Zhang RL, et al: Matrix
metalloproteinase 2 (MMP2) and MMP9 secreted by
erythropoietin-activated endothelial cells promote neural
progenitor cell migration. J Neurosci. 26:5996–6003. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahmadi SA, Moinfar M, Gohari Moghaddam K
and Bahadori M: Practical application of angiogenesis and
vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med.
13:498–503. 2010.PubMed/NCBI
|
|
19
|
Sharma N, Seftor RE, Seftor EA, et al:
Prostatic tumor cell plasticity involves cooperative interactions
of distinct phenotypic subpopulations: role in vasculogenic
mimicry. Prostate. 50:189–201. 2002. View Article : Google Scholar
|
|
20
|
van der Schaft DW, Hillen F, Pauwels P, et
al: Tumor cell plasticity in Ewing sarcoma, an alternative
circulatory system stimulated by hypoxia. Cancer Res.
65:11520–11528. 2005.PubMed/NCBI
|
|
21
|
Liu WB, Xu GL, Jia WD, et al: Prognostic
significance and mechanisms of patterned matrix vasculogenic
mimicry in hepatocellular carcinoma. Med Oncol. 28:S228–S238. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun T, Sun BC, Zhao XL, et al: Promotion
of tumor cell metastasis and vasculogenic mimicry by way of
transcription coactivation by Bcl-2 and Twist1: a study of
hepatocellular carcinoma. Hepatology. 54:1690–1706. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baeten CI, Hillen F, Pauwels P, de Bruine
AP and Baeten CG: Prognostic role of vasculogenic mimicry in
colorectal cancer. Dis Colon Rectum. 52:2028–2035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue WY and Chen ZP: Does vasculogenic
mimicry exist in astrocytoma? J Histochem Cytochem. 53:997–1002.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun B, Zhang D, Zhang S, Zhang W, Guo H
and Zhao X: Hypoxia influences vasculogenic mimicry channel
formation and tumor invasion-related protein expression in
melanoma. Cancer Lett. 249:188–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao N, Sun BC, Sun T, et al:
Hypoxia-induced vasculogenic mimicry formation via VE-cadherin
regulation by Bcl-2. Med Oncol. 29:3599–3607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gomez-Pinillos A and Ferrari AC: mTOR
signaling pathway and mTOR inhibitors in cancer therapy. Hematol
Oncol Clin North Am. 26:483–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
|
29
|
Li XY, Zhang LQ, Zhang XG, et al:
Association between AKT/mTOR signalling pathway and malignancy
grade of human gliomas. J Neurooncol. 103:453–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Itzhaki O, Greenberg E, Shalmon B, et al:
Nicotinamide inhibits vasculogenic mimicry, an alternative
vascularization pathway observed in highly aggressive melanoma.
PLoS One. 8:e571602013. View Article : Google Scholar
|
|
31
|
Serwe A, Rudolph K, Anke T and Erkel G:
Inhibition of TGF-β signaling, vasculogenic mimicry and
proinflammatory gene expression by isoxanthohumol. Invest New
Drugs. 30:898–915. 2012.
|
|
32
|
Iwamaru A, Kondo Y, Iwado E, et al:
Silencing mammalian target of rapamycin signaling by small
interfering RNA enhances rapamycin-induced autophagy in malignant
glioma cells. Oncogene. 26:1840–1851. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li C, Liu Y, Liu J, et al: Rapamycin
inhibits human glioma cell proliferation through down-regulating
mammalian target of rapamycin pathway and up-regulating
microRNA-143. Head Neck Oncol. 4:662012.
|
|
34
|
Heimberger AB, Wang E, McGary EC, et al:
Mechanisms of action of rapamycin in gliomas. Neuro Oncol. 7:1–11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Misra RM, Bajaj MS and Kale VP:
Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role
of HIF-1α-neuropilin-1 axis. PLoS One. 7:e501532012.PubMed/NCBI
|
|
36
|
Hendrix MJ, Seftor EA, Meltzer PS, et al:
Expression and functional significance of VE-cadherin in aggressive
human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad
Sci USA. 98:8018–8023. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hess AR, Seftor EA, Gruman LM, Kinch MS,
Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive
melanoma cells through a novel signaling pathway: implications for
vasculogenic mimicry. Cancer Biol Ther. 5:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen LX, He YJ, Zhao SZ, et al: Inhibition
of tumor growth and vasculogenic mimicry by curcumin through
down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal
melanoma model. Cancer Biol Ther. 11:229–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
40
|
Seftor RE, Seftor EA, Kirschmann DA and
Hendrix MJ: Targeting the tumor microenvironment with chemically
modified tetracyclines: inhibition of laminin 5 gamma2 chain
promigratory fragments and vasculogenic mimicry. Mol Cancer Ther.
1:1173–1179. 2002.
|
|
41
|
Kirschmann DA, Seftor EA, Hardy KM, Seftor
RE and Hendrix MJ: Molecular pathways: vasculogenic mimicry in
tumor cells: diagnostic and therapeutic implications. Clin Cancer
Res. 18:2726–2732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z
and Zhou Q: Tumour vasculogenic mimicry is associated with poor
prognosis of human cancer patients: a systemic review and
meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ballou LM and Lin RZ: Rapamycin and mTOR
kinase inhibitors. J Chem Biol. 1:27–36. 2008. View Article : Google Scholar
|
|
44
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
